Clinical Observation On Sanxiao Decoction For Cough Variant Asthma(External Cold And Internal Heat Type)

Objective: To observe and test the clinical efficacy and safety of using Sanxiao Tang to treat patients with cough variant asthma(external cold and internal heat syndrome).Explore the effective methods of using traditional Chinese medicine to treat cough variant asthma in order to achieve the purpose of controlling patients' cough symptoms,delaying disease progression and improving quality of life.Methods: A randomized control method was used to divide 108 patients with CVA who met the diagnostic criteria into 36 cases of control group,36 cases of treatment group 1 and36 cases of treatment group 2.The control group was treated with inhaled salmeterol ticasone powder inhalation and oral montelukast sodium tablets;the treatment group 1 was given the traditional Chinese medicine Sanxiaotang formula granules in the above-mentioned Western medicine treatment;the treatment group 2 was given Sanxiaotang only Formula granule treatment;the treatment period of the three groups of patients is 2 weeks.After the course of treatment,the drug was stopped and followed up for 2 months.The cough symptom score,secondary symptom score,Fe NO level,Leicester cough questionnaire score(LCQ),safety index and relapse were recorded before and after treatment in the three groups of patients,and the statistical data was statistically analyzed using statistical software SPSS23.0.Result:1.A total of 108 cases were included in this study,with 7 cases falling off,and the final effective case was 101 cases.Among them,33 cases in the control group,34 cases in the treatment group 1,and 34 cases in the treatment group 2.The gender composition,age and distribution of disease course of the three groups were statistically tested.There was no significant difference between the groups(P> 0.05),and the three groups were comparable.2.Comparison of clinical efficacy differences among the three groups,treatment group 1was significantly better than the other two groups(P <0.05),there was no statistically significant difference between treatment group 2 and control group(P> 0.05).3.In terms of the score of cough main symptoms,the three groups of patients have improved to varying degrees after treatment(P <0.05),and the treatment group 1 is significantly better than the other two groups(P <0.05),there is no difference between the treatment group 2 and the control group Significant difference(P> 0.05).4.In terms of scores of secondary symptoms,the three groups of patients have different degrees of improvement before and after treatment(P <0.05),and the treatment group 1 is significantly better than the other two groups(P <0.05).The treatment group 2 and the control group except for cold,Except for pharyngeal dryness,there was no significant difference between the two groups(P> 0.05).5.In terms of FeNO concentration level,the three groups of patients had different degrees of reduction after treatment(P <0.05),and treatment group 1 was significantly better than the other two groups(P <0.05),there was no obvious difference between treatment group 2and control Difference(P> 0.05).6.In terms of LCQ scores,the quality of life scores of the three groups of patients all improved after treatment(P <0.05).In terms of physiological score,psychological score and total score,there were differences between the two treatment groups and the control group(P <0.05),and there was no significant difference between the treatment group 1 and the treatment group 2(P> 0.05).The social scores of the three groups were roughly the same,with no statistical difference(P> 0.05).7.The three groups of patients had different symptoms recurrence(P <0.05),and the treatment group 1 was significantly lower than the other two groups(P <0.05),and there was no significant difference between the treatment group 2 and the control group(P>0.05).8.In terms of safety indicators,there was no abnormality in the comparison between the three groups before and after treatment,and the difference was not statistically significant(P> 0.05).Conclusion: The use of Sanxiaotang combined with Western medicine to treat cough variant asthma(external cold and internal heat syndrome)with the effect of relieving external cold and internal clearing phlegm and heat can further improve the cough symptoms of patients,compared with Sanxiaotang and Western medicine alone Improving Fe NO levels,improving the quality of life,and reducing the recurrence rate provide an effective treatment method for the clinic,and are safe during treatment,and are worthy of clinical promotion and application.